From: A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer
Number
Percentage (%)
Assessable patients
54
100
Overall response
18
33.3
CR
1
1.9
PR
17
31.5
SD
27
50.0
PD
9
16.7
DCR (CR + PR + SD)
45
83.3